Total Health Care
Welcome,         Profile    Billing    Logout  
 9 Trials 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gordon, Michael S
NCT05944952: Low-dose Versus a High-dose Sublingual Buprenorphine Induction

Recruiting
4
40
US
buprenorphine/naloxone, suboxone
Friends Research Institute, Inc., MATClinics
Opioid Use Disorder
10/24
12/24
NCT03340506 / 2017-001987-39: Dabrafenib and/or Trametinib Rollover Study

Recruiting
4
100
Europe, Japan, US, RoW
dabrafenib, trametinib
Novartis Pharmaceuticals
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
12/27
12/27
NCT02867124: Long-acting Naltrexone for Pre-release Prisoners

Recruiting
3
240
US
XR-NTX, long-acting naltrexone, place of residence, residence, opioid treatment program, OTP
Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)
Opiate Addiction
02/25
06/25
NCT06306443: Buprenorphine for Individuals in Jail

Not yet recruiting
3
240
US
extended-release buprenorphine (XR-B), sublingual buprenorphine (SL-B)
Friends Research Institute, Inc.
Opioid Use Disorder
12/27
12/28
NCT03616236: Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment

Recruiting
3
320
US
Buprenorphine/Naloxone, BBT, Treatment as usual, TAU
Friends Research Institute, Inc.
Opioid Use
12/25
06/26
NCT04408313: Extended Release Naltrexone Versus Extended Release Buprenorphine with Individuals Leaving Jail

Recruiting
2/3
240
US
XR-B, extended-release buprenorphine, XR-NTX, extended-release naltrexone
Friends Research Institute, Inc.
Opioid-use Disorder
06/25
12/25
COMMANDER-001, NCT05357898: Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Terminated
1/2
20
US
SQZ-eAPC-HPV, Pembrolizumab
SQZ Biotechnologies
Adult Solid Tumor
11/23
11/23
NCT05094804 / 2022-002234-14: A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

Recruiting
1/2
172
US
OR2805, Cemiplimab, Libtayo, Docetaxel, Taxotere
OncoResponse, Inc., OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
04/24
08/24
NKT2152-101, NCT05119335: A Study of NKT2152, a HIF2α Inhibitor, in Patients with Advanced Clear Cell Renal Cell Carcinoma

Active, not recruiting
1/2
128
US
Oral NKT2152
NiKang Therapeutics, Inc.
CcRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
05/25
09/26
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Terminated
1
5
US
DCBY02
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
02/24
02/24
C-800-01, NCT03860272: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Recruiting
1
550
Europe, US
Botensilimab, AGEN1181, Anti-CTLA-4, Balstilimab, AGEN2034, Anti-PD-1
Agenus Inc.
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
12/26
12/26
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer

Recruiting
1
66
US, RoW
INV-9956
Shenzhen Ionova Life Sciences Co., Ltd.
Advanced Metastatic Castration Resistant Prostate Cancer
04/26
03/27
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

Recruiting
1
257
US, RoW
DCSZ11, Pembrolizumab
DynamiCure Biotechnology
Advanced or Metastatic Solid Tumors
12/25
12/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Mitchell, Shannon G
POLY, NCT05766631: Treating Polysubstance Use Using a Novel Digital Technology

Recruiting
3
240
US
DynamiCare Health, DCH, Methadone Treatment-As-Usual
Friends Research Institute, Inc., National Institute on Drug Abuse (NIDA)
Opioid Use, Opioid Use Disorder, Cocaine Use, Cocaine Use Disorder
06/27
09/27
Kirk, Arethusa S
No trials found
Couvillion, Kathy
No trials found

Download Options